Last updated: July 9, 2026
BUTRANS revenue exposure is driven by (1) transdermal buprenorphine category penetration, (2) FDA-controlled supply for chronic pain indications, and (3) the timing and risk profile of generic and authorized-duplicate entries against the Orange Book and relevant exclusivities. In US product terms, BUTRANS is positioned as a “late-life” brand asset where the dominant investment question is not discovery optionality but defensibility against generic switching, payor uptake, and any remaining formulation or method-of-use patent tails.
What is BUTRANS (buprenorphine transdermal system) and what drives its US market fundamentals?
BUTRANS is a transdermal delivery system of buprenorphine indicated for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatments are inadequate (US label). The commercial thesis is built on chronic pain management where clinicians favor steady-state opioid delivery to reduce peak-trough effects versus immediate-release oral opioids.
Core demand drivers
- Patient segmentation: chronic pain requiring long-term opioid therapy with need for stable plasma buprenorphine levels.
- Prescriber behavior: conversion from oral opioids based on adherence and tolerability.
- Payor policy: prior authorization and quantity controls for transdermal opioids versus alternatives.
- Safety and monitoring: opioid risk management programs and clinician selection criteria.
Commercial mechanics investors underwrite
- Switching elasticity: how rapidly payors and prescribers adopt lower-cost buprenorphine alternatives when branded exclusivity erodes.
- Net revenue per script: discounting intensity and channel mix (retail vs specialty).
- Back-end opportunity: line extensions (dose strengths, patch sizes, packaging) and contracting leverage.
What patents protect BUTRANS in the US, and how strong is the patent estate for buprenorphine patches?
A complete, accurate US “who owns what” view requires the Orange Book patent listing set for BUTRANS and the underlying suit records tied to those listings. Without that listing dataset and litigation docket evidence in this input, a defensible patent count, expiration map, and claim-scope strength scoring cannot be produced.
Investment relevance
- Generic entry risk is determined by whether any listed patents remain enforceable and by whether a generic challenger can carve out design-arounds or avoid infringement.
- If only broad formulation or use claims remain, litigation leverage tends to compress into short settlement windows rather than multi-year exclusivity.
How investors typically benchmark estate strength (framework)
- Number of Orange Book listed patents tied to the NDA.
- Remaining life for each key patent family.
- Whether the strongest patents are formulation/device layer or method-of-use.
- Litigation posture: TRO/PI history, court construction outcomes, and any Federal Circuit affirmances.
When does BUTRANS lose exclusivity in the US, and what are the key timeline inflection points?
Exclusivity timing depends on:
- Patent expiration(s) for Orange Book-listed patents.
- Any FDA exclusivity grants (new chemical entity, new clinical investigation, 505(b)(2) exclusivity) tied to the NDA’s regulatory history.
- Patent expiry plus potential 180-day exclusivity triggers for ANDA Paragraph IV filers.
A complete exclusivity timeline cannot be constructed from the current input without Orange Book and exclusivity history.
Decision-useful timeline structure for underwriting
- Patent-expiration date for the last blocking patent.
- “First generic filing” date if Paragraph IV exists.
- Any settlement-triggered “moratorium” date.
- ANDA approval date and launch lead time for bioequivalence/CMC completion.
What is the Orange Book status of BUTRANS, and what patents are listed for ANDA/505(b)(2) applicants?
The Orange Book status requires the NDA’s listing table and each associated patent number, claim type (composition, formulation, method of use), and expiration date.
A precise Orange Book table (patent numbers, expiration dates, remaining terms, listed claim scopes) cannot be produced without that listing content in the prompt.
What Paragraph IV challenges exist for BUTRANS, and what generic entry risks follow?
Paragraph IV risk assessment requires:
- Identifying any ANDA challengers to BUTRANS.
- Mapping their ANDA filing date, claimed patents, and Paragraph IV certifications.
- Following litigation outcomes and any settlement terms (trigger dates, agreed launch caps, design-around commitments).
No such docket-specific information is provided in the input, so a factual assessment of challenges and their effect on entry timing cannot be delivered.
Which companies are likely competing with BUTRANS, including authorized generics and generic ANDA brands?
A competitor landscape requires:
- Named ANDA holders and likely filers from Orange Book entries and litigation records.
- Any authorized-duplicate agreements, if present, tied to the NDA or marketing rights.
- Foreign or internal competitor activity if it affects US market share via pricing and supply.
The current input contains no competitor list or Orange Book challenger data, so an actionable competitor map cannot be generated.
How do BUTRANS patents and exclusivity compare with other transdermal buprenorphine products?
A defensible comparison needs:
- Product-by-product Orange Book and exclusivity timelines for each transdermal buprenorphine competitor (different NDA numbers, strength-specific formulations, or device/technology variations).
- Patent claim-type alignment across products.
Without those datasets, cross-product patent and expiry comparisons would risk being incomplete or incorrect.
What formulations are protected for BUTRANS, and how do formulation design-arounds affect infringement risk?
For patch products, “design-around” pathways often include:
- Different adhesive systems or backing layers
- Different drug-in-adhesive matrices
- Alternative release-rate modifiers
- Packaging and rate-control elements affecting in-use drug delivery profile
A factual claim-scope analysis requires the specific formulation patents and the claim language. That information is absent from the input.
What method-of-use or clinical-use patents could affect generic substitution of BUTRANS?
If BUTRANS has any listed method-of-use patents, generic labels may be restricted to “carve-out” dosing language or indication-limited labeling. The practical effect is payor policy gating, as many formularies tie coverage criteria to the labeled indication.
A method-of-use risk analysis requires the Orange Book listing claim types and associated patents. No listing content is available in the input.
What FDA regulatory pathway issues matter for BUTRANS investors: ANDA, 505(b)(2), REMS, and labeling controls?
Investment-relevant regulatory controls include:
- Whether ANDA applicants can rely on existing in vivo/bioavailability data for the patch matrix.
- Labeling constraints arising from patent carve-outs.
- Controlled substance and REMS-like operational requirements (operational rather than a classic REMS program unless specified by FDA).
- Manufacturing CMC comparability for transdermal drug delivery systems.
A precise “regulatory pathway risk” assessment requires NDA history and the FDA submission/approval landscape for BUTRANS. That material is not included in the input.
What patent litigation affects BUTRANS, and how does settlement timing influence launch?
This section requires:
- Court case numbers, parties, asserted patents, claim constructions, and outcomes.
- Any settlement agreements that set launch dates or moratoriums.
- Any injunctions or stays tied to patent validity/infringement.
No litigation dataset is provided, so this cannot be answered with hard data.
What settlement agreements exist for BUTRANS and what triggers generic launch dates?
Settlement analysis requires the actual settlement terms or at least filed public summaries showing:
- Trigger conditions (stockpiling limits, mutual dismissal with prejudice)
- Launch date commitments and design-around specifications
- Per-patent or per-assertion entry caps
This information is not in the input, so a factual settlement section would be fabricated.
What manufacturing/IP barriers exist for BUTRANS patches that could slow generic CMC and scale?
Transdermal systems can face barriers related to:
- Reproducible release kinetics across scales
- Adhesive tack profile and skin compatibility
- Stability under humidity/temperature cycling
- In-process control strategies for uniform drug distribution
A credible manufacturing/IP barrier assessment needs the specific patents covering manufacturing methods (if any) and any known FDA observations or CMC-related rejection patterns for comparable transdermal ANDAs. The current input lacks both.
Revenue exposure: how much does BUTRANS depend on exclusivity vs share protection, and what happens in a generic-switch scenario?
Without financial disclosure or unit share data in the input, the only investment-safe statement is structural:
- If exclusivity is eroded and generic substitutes are priced lower, payor formularies often shift quickly, especially when clinical equivalence is established and labeling carve-outs do not prevent preferred positioning.
- Patch chronic pain markets typically show high reimbursement leverage from payors, so gross-to-net compression and formulary placement determine durability post-entry.
A quantified revenue bridge and scenario model cannot be produced from the current input.
Key Takeaways
- BUTRANS investment fundamentals are exclusivity-plus-formulary: the dominant risk is generic switching timing relative to remaining enforceable patent and any FDA exclusivity tail.
- The patent estate and Orange Book listing set are the controlling inputs for entry risk, but the listing and litigation datasets are not present in the prompt, so a factual patent timeline, Paragraph IV map, and settlement-trigger calendar cannot be responsibly generated.
- In transdermal opioid categories, CMC reproducibility and labeling controls often determine whether generic approvals translate into immediate formulary wins; those factors require product-specific regulatory and patent claim evidence.
FAQs
- How does Orange Book “claim type” (composition vs method of use) change ANDA label restrictions for BUTRANS?
- What are the typical generic launch timelines for transdermal buprenorphine ANDAs once approved by FDA?
- How do payor prior authorization criteria for long-term opioid therapy affect switching from BUTRANS to generics?
- What formulation parameters (adhesive system, drug-in-adhesive matrix, release rate) most influence generic patch performance and litigation risk?
- What settlement terms in opioid patch patent cases most commonly control the effective entry date despite patent expiry?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via Orange Book database).
- FDA. Drug Development and Drug Interactions (ANDA/505(b)(2) regulatory framework materials).
